| CHOW | CHOW diet |
| HFD | High-fat diet |
| VAT | Visceral adipose tissue |
| VA | Visceral adipocyte |
| BAT | Brown adipose tissue |
| PAT | Perivascular adipose tissue |
| SAT | Subcutaneous adipose tissue |
| GAS | Gastrocnemius |
| OGTT | Oral glucose tolerance test (OGTT) |
| ITT | Insulin tolerance test |
| NTA | Nanoparticle tracking analysis |
| TEM | Transmission electron microscopy |
| HFD VA | High-fat diet visceral adipocyte |
| HFD VAD-ev | High-fat diet visceral adipocyte -derived extracellular vesicle |
| CO-HFD VA | C2C12 cells were seeded in the lower chamber of Transwell plates, while HFD VA cells were plated in the upper chamber |
| CO-GW4869 | C2C12 cells were seeded in the lower chamber of Transwell plates, while HFD VA cells were plated in the upper chamber with GW4869 |
| HFD+DMSO | HFD mice were intraperitoneally injected with DMSO |
| HFD+GW4869 | HFD mice were intraperitoneally injected with GW4869 |
| F4/80 | Mouse egf-like module-containing mucin-like hormone receptor-like 1 |
| CD11b | Cyclin-dependent kinase 11b |
| CD86 | T-lymphocyte activation antigen CD86 |
| CD206 | Macrophage mannose receptor 1 |
| MyoD | Myoblast determination protein |
| PAX7 | Paired box protein PAX-7 |
| MyoG | Myogenic |
| MYH3 | Myosin heavy chain 3 |
| FBXO32 | Recombinant f-box protein 32 |
| Trim63 | Tripartite motif-containing protein 63 |
| CCL2 | C C motif ligand 2 |
| IL-6 | Interleukin 6 |
| IL-1β | Interleukin 1β |
| iNOS | Nstitute nacional de obras sanitarias |
| TNFa | Tumor necrosis factor-a |
| M0+Ev-NC | RAW264.7 cells treated for 24 h with HFD VAD-evs loaded with the miR-155 inhibitor negative control. |
| M0+Ev-miR155 inhibitor | RAW264.7 cells treated for 24 h with HFD VAD-evs loaded with miR-155 inhibitor. |
| AAV-NC | AAV vector treatment was used as the negative control |
| HFD+AAV NC | AAV NC was injected intraperitoneally on the first day and via the tail vein on the third day, respectively (100 μL/day, start at 9 weeks of age). |
| HFD+AAV-155 | AAV-155 was injected intraperitoneally on the first day and via the tail vein on the third day, respectively (100 μL/day, start at 9 weeks of age). |
| SFCM | SFCM was harvested from RAW264.7 cells treated for 24 h with HFD VAD-evs |
| SFCM NCev | SFCM was harvested from RAW264.7 cells treated for 24 h with HFD VAD-evs loaded with the miR-155 inhibitor negative control. |
| SFCM INev | SFCM was harvested from RAW264.7 cells treated for 24 h with HFD VAD-evs loaded with miR-155 inhibitor. |